

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)



(10) International Publication Number
WO 2022/208269 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/IB2022/052782

(22) International Filing Date:
25 March 2022 (25.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/167,440 29 March 2021 (29.03.2021) US
63/291,666 20 December 2021 (20.12.2021) US

(71) Applicant: **ARBUTUS BIOPHARMA CORPO-
RATION** [CA/CA]; 100 - 8900 Glenlyon Parkway, Burn-
aby, British Columbia V5J 5J8 (CA).

(72) Inventors: **AHUJA, Vijay**; 301 Trinity Court, Apt. 1,
Princeton, New Jersey 08540 (US). **COLE, Andrew G.**;
65 Rocky Brook Road, Cranbury, New Jersey 08512 (US).
DORSEY, Bruce D.; 1213 Meetinghouse Road, Ambler,
Pennsylvania 19002 (US). **FAN, Yi**; 40 Bittersweet Drive,
Doylestown, Pennsylvania 18901 (US). **HEFFERNAN,
Gavin D.**; 616 East 6th Street, Florence, New Jersey 08518
(US). **KAKARLA, Ramesh**; 11584 Jaguar Court, San
Diego, California 92131 (US). **KULTGEN, Steven G.**;
1526 Russett Drive, Warminster, Pennsylvania 18974 (US).
NGUYEN, Duyan; 106 Cypress Drive, Ambler, Pennsyl-
vania 19002 (US). **OZTURK, Seyma**; 696 Holland Road,
Southampton, Pennsylvania 18966 (US). **QUINTERO,
Jorge**; 819 Marlowe Road, Cherry Hill, New Jersey 08003
(US). **SOFIA, Michael J.**; 3066 Antler Drive, Doylestown,
Pennsylvania 18902 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(54) Title: SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS,
AND METHODS USING SAME

(57) Abstract: The present disclosure includes substituted 1-aryl-1'-heteroaryl compounds, substituted 1,1'-biheteroaryl compounds,
analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the disclosure can be used to
treat, ameliorate, and/or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the
compounds contemplated in the disclosure can be used to treat, ameliorate, and/or prevent cancer in a patient.



WO 2022/208269 A2